GlaxoSmithKline Pharmaceuticals Complete Financial Statements
GLAXO • Review detailed financials to uncover trends, confirm thesis & journal trades
11 Years of Data
2025 - 2015
Complete Financial Data Export
Export complete financial statements for GlaxoSmithKline Pharmaceuticals (GLAXO).
Downloads include all available records across all periods.
For market performance, see the
GLAXO stock price today
.
Profitability Ratios
Net Profit Margin
25.39%
2025 data
EBITDA Margin
36.61%
2025 data
Operating Margin
34.00%
2025 data
Return on Assets
6.28%
2025 data
Return on Equity
13.22%
2025 data
Balance Sheet Ratios
Current Ratio
13.53
2025 data
Debt to Equity
2.11
2025 data
Equity Ratio
47.49%
2025 data
Asset Turnover
0.25
2025 data
Year-over-Year Growth Analysis
Comparing Sept 2024 vs Sept 2025
Revenue Growth
-3.2%
Year-over-Year
Net Profit Growth
+2.0%
Year-over-Year
EBITDA Growth
+3.0%
Year-over-Year
Expense Growth
-6.5%
Year-over-Year
Assets Growth
+15.5%
Year-over-Year
Equity Growth
+9.7%
Year-over-Year
Liabilities Growth
+15.5%
Year-over-Year
Operating Cash Flow Growth
+121.6%
Year-over-Year
Investing Cash Flow Growth
-611.1%
Year-over-Year
Financing Cash Flow Growth
-36.8%
Year-over-Year
Income Statement
Periods
₹ Crores
| Particulars | Sept 2025 | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Jun 2018 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,016 | 1,015 | 849 | 1,050 | 962 | 850 | 985 | 985 | 826 | 815 | 833 | 939 | 2,132 | 776 | 826 | 964 | 785 | 764 | 838 | 888 | 803 | 707 | 834 | 1,299 | 823 | 819 | 795 | 831 | 754 | 871 |
| Expenses | 644 | 641 | 554 | 689 | 673 | 584 | 658 | 668 | 618 | 618 | 751 | 660 | 634 | 596 | 585 | 678 | 707 | 586 | 636 | 739 | 602 | 535 | 611 | 688 | 588 | 623 | 1,408 | 663 | 608 | 688 |
| EBITDA | 372 | 374 | 295 | 361 | 290 | 266 | 327 | 318 | 208 | 198 | 83 | 279 | 1,497 | 180 | 241 | 286 | 78 | 178 | 202 | 150 | 201 | 172 | 223 | 611 | 236 | 196 | -613 | 168 | 145 | 183 |
| Operating Profit Margin % | 34.00% | 34.00% | 31.00% | 32.00% | 28.00% | 28.00% | 31.00% | 30.00% | 22.00% | 19.00% | 7.00% | 28.00% | 22.00% | 20.00% | 27.00% | 27.00% | 5.00% | 18.00% | 22.00% | 16.00% | 22.00% | 18.00% | 23.00% | 22.00% | 22.00% | 21.00% | -81.00% | 19.00% | 17.00% | 17.00% |
| Depreciation | 17 | 15 | 16 | 17 | 18 | 16 | 19 | 18 | 17 | 16 | 17 | 16 | 15 | 16 | 16 | 17 | 18 | 18 | 18 | 22 | 23 | 22 | 18 | 23 | 14 | 19 | 18 | 12 | 11 | 12 |
| Interest | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 3 | 0 | 0 | 0 |
| Profit Before Tax | 354 | 359 | 279 | 344 | 271 | 249 | 308 | 299 | 190 | 181 | 65 | 262 | 1,482 | 163 | 224 | 268 | 60 | 160 | 184 | 127 | 177 | 149 | 204 | 587 | 222 | 176 | -634 | 157 | 134 | 171 |
| Tax | 97 | 96 | 74 | 91 | 76 | 67 | 78 | 82 | 57 | 49 | 20 | 69 | 263 | 44 | 60 | 64 | 45 | 39 | 34 | 51 | 39 | 38 | 48 | 85 | 75 | 63 | 27 | 56 | 50 | 57 |
| Net Profit | 258 | 263 | 205 | 253 | 195 | 182 | 230 | 218 | 133 | 132 | 46 | 193 | 1,219 | 119 | 165 | 204 | 14 | 121 | 150 | 77 | 138 | 111 | 157 | 503 | 147 | 114 | -661 | 101 | 84 | 114 |
| Earnings Per Share (₹) | 15.07 | 15.52 | 12.10 | 14.67 | 11.37 | 10.76 | 13.57 | 12.84 | 7.41 | 7.04 | 9.89 | 11.42 | 71.96 | 7.04 | 9.71 | 12.06 | 0.85 | 7.14 | 8.87 | 4.51 | 8.15 | 6.54 | 10.26 | 29.68 | 8.67 | 6.70 | -39.03 | 5.95 | 9.93 | 6.71 |
Related Pages for GlaxoSmithKline Pharmaceuticals
Additional stock information and data for GLAXO
Balance Sheet
Years
Annual Data
₹ Crores
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 4,108 | 3,557 | 3,327 | 4,633 | 3,115 | 3,136 | 3,911 | 3,948 | 3,004 | 3,055 | 3,216 |
| Current Assets | 3,410 | 2,798 | 2,494 | 3,708 | 2,203 | 1,775 | 2,010 | 2,186 | 1,674 | 2,174 | 2,587 |
| Fixed Assets | 284 | 321 | 330 | 331 | 387 | 758 | 432 | 325 | 258 | 210 | 123 |
| Capital Work in Progress | 14 | 14 | 20 | 31 | 13 | 120 | 1,003 | 923 | 606 | 268 | 115 |
| Investments | 1,118 | 813 | 518 | 366 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 2,692 | 2,408 | 2,458 | 3,907 | 2,715 | 2,257 | 2,477 | 2,700 | 2,140 | 2,577 | 2,977 |
| LIABILITIES | |||||||||||
| Total Liabilities | 4,108 | 3,557 | 3,327 | 4,633 | 3,115 | 3,136 | 3,911 | 3,948 | 3,004 | 3,055 | 3,216 |
| Current Liabilities | 252 | 254 | 259 | 272 | 282 | 291 | 317 | 290 | 277 | 292 | 280 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | 1,951 | 1,778 | 1,741 | 2,663 | 1,478 | 1,821 | 2,140 | 2,057 | 2,007 | 2,183 | 1,829 |
| Share Capital | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 85 | 85 | 85 | 85 |
| Reserves & Surplus | 1,782 | 1,608 | 1,572 | 2,494 | 1,309 | 1,651 | 1,970 | 1,973 | 1,922 | 2,099 | 1,744 |
Cash Flow Statement
Periods
₹ Crores
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,290 | 582 | 484 | 811 | 578 | 491 | 410 | 473 | 234 | 139 | 338 |
| Investing Activities | -46 | 9 | 808 | -406 | 418 | -57 | -153 | -104 | 301 | 499 | 180 |
| Financing Activities | -769 | -562 | -1,543 | -524 | -696 | -428 | -358 | -307 | -511 | -638 | -497 |
| Net Cash Flow | 475 | 29 | -251 | -119 | 300 | 6 | -102 | 62 | 24 | 0 | 21 |